Pamiparib
A PARP inhibitor used in cancer treatment
| Pamiparib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Pamiparib is a PARP inhibitor that is used in the treatment of certain types of cancer. It is particularly utilized in the management of ovarian cancer and other malignancies associated with BRCA mutations.
Mechanism of Action[edit]
Pamiparib functions by inhibiting the enzyme poly ADP ribose polymerase (PARP). PARP plays a critical role in the repair of single-strand DNA breaks through the base excision repair pathway. By inhibiting PARP, pamiparib prevents the repair of single-strand breaks, leading to the accumulation of double-strand breaks during DNA replication. In cells with deficient homologous recombination repair mechanisms, such as those with BRCA1 or BRCA2 mutations, this accumulation of DNA damage can lead to cell death.
Clinical Use[edit]
Pamiparib is primarily used in the treatment of ovarian cancer, particularly in patients with BRCA mutations. It is also being investigated for use in other types of cancer, including breast cancer and prostate cancer. The drug is administered orally and is often used in patients who have already undergone other forms of chemotherapy.
Side Effects[edit]
Common side effects of pamiparib include nausea, fatigue, anemia, and thrombocytopenia. More serious side effects can include myelodysplastic syndrome and acute myeloid leukemia, although these are less common. Patients undergoing treatment with pamiparib require regular monitoring of their blood counts and overall health.
Development and Approval[edit]
Pamiparib was developed by BeiGene, a biotechnology company. It has undergone various clinical trials to assess its efficacy and safety in treating different types of cancer. The drug has been approved for use in several countries and continues to be the subject of ongoing research.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
